93
Participants
Start Date
March 20, 2023
Primary Completion Date
April 30, 2026
Study Completion Date
July 31, 2027
IGV-001 Cell Immunotherapy
IGV-001, an immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers.
Placebo
Placebo in implantable biodiffusion chambers containing a predetermined inactive solution.
Standard of Care (SOC): Radiation Therapy
Radiation therapy administered per institutional standards.
SOC: Temozolomide
Temozolomide administered orally.
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center, New York
Weill Cornell Medicine, New York
Lenox Hill Hospital, New York
Montefiore Medical Center, The Bronx
Westchester Medical Center, Valhalla
Northwell Health at North Shore University Hospital, Manhasset
The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center, Hershey
Thomas Jefferson University, Philadelphia
University of Pennsylvania, Philadelphia
West Virginia University, Morgantown
University of North Carolina (UNC) - Chapel Hill, Chapel Hill
Mayo Clinic - Jacksonville, Jacksonville
The Ohio State University (OSU) Wexner Medical Center, Columbus
UC Health, Cincinnati
Henry Ford Health System, Detroit
University of Wisconsin - Madison, Madison
Tufts Medical Center, Boston
Dartmouth Hitchcock Medical Center, Lebanon
John Theurer Cancer Center At Hackensack UMC, Hackensack
Jersey Shore University Medical Center, Neptune City
Rhode Island Hospital, Providence
Lead Sponsor
Imvax
INDUSTRY